Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biofrontera Awarded grant:
+++++++++++++++++++++
http://www.prnewswire.co.uk/cgi/news/release?id=117283
+++++++++++++++++++++
News Release
Wednesday 18 February 2004, 9:30 GMT Wednesday 18 February 2004
HEALTH
MEDICAL
BUSINESS
Biofrontera Pharmaceuticals Holding AG
Biofrontera Wins EUR 4 Mio Research Grant
LEVERKUSEN, Germany, February 18 /PRNewswire/ -- Biofrontera Pharmaceuticals GmbH, Leverkusen, today announced that it obtained funding by the state government of North Rhine-Westphalia. The company will receive 4 mio. EUR over the next 2 years. The research grant is aimed at supporting the discovery of innovative drug candidates for the treatment of chronic Pain and Parkinson's Disease. Biofrontera Pharmaceuticals GmbH is a wholly-owned subsidiary of Biofrontera AG, a neuroscience company based on natural compound discovery.
"This generous support confirms the quality of Biofrontera's outstanding pharmaceutical research platform. The funding helps us to advance research projects in our core-areas Pain and Parkinson" commented Prof. Hermann Lübbert, CEO of Biofrontera AG. "With its Technology and Innovation Program, the government of North Rhine-Westphalia made a clear commitment to the support of biotechnology."
"We have initiated the TIP Program to help technology companies during the time and cost intensive research period, which precedes product sales in such businesses," explained Harald Schartau, Minister for Economic Affairs in NRW. "We are pleased that a first-class company like Biofrontera AG has chosen NRW for its headquarters. We take pride in supporting research-intensive companies in their development."
Biofrontera has a unique natural compound collection and strength in natural compound modification, which it combines with proprietary molecular and in vivo pharmacology, to build a pipeline of novel CNS drugs. All technology modules are made available for contract research.
http://www.biofrontera.com
Distributed by PR Newswire on behalf of Biofrontera Pharmaceuticals Holding AG
--------------------------------------------------------------------------------
PR Newswire Europe Ltd.
209 - 215 Blackfriars Road, London, SE1 8NL
Tel : +44 (0)20 7490 8111
Fax : +44 (0)20 7490 1255
E-mail : info@prnewswire.co.uk
Copyright © 2005 PR Newswire Europe Limited. All rights reserved.
A United Business Media Company.
Terms and conditions of use apply.
Of course this is subject to comment by people who will complain about the amount, or the purpose, or the -- yada yada yada... but then it's better than getting nothing right?
Stakddek
This sounds very familiar????
+++++++++++++++
http://www.lab21.com/web/index.php
+++++++++++++++ A clip from the site.+++++++++++++
Join the growing list of LAB21 devotees who have discovered how DNA Face Cream is dramatically more effective than conventional skincare products. LAB21's DNA Face Cream is custom formulated based on the analysis of an individual's DNA. In order to begin the process of ordering DNA Face Cream, a DNA Test is required. Based on the overwhelming response from viewers of The CBS Evening News, MSNBC, CNN and many other prominent national news programs, LAB21 has developed an At Home DNA Test Kit which can be self-administered by the individual at home.
Each At Home DNA Test Kit contains a booklet on How to Self-Administer your Skin DNA Test, a DNA Face Cream brochure, 2 packs of sterile cotton swabs, a DNA Swab Collection envelope, SkinProfile™ questionnaire, and postage paid envelope. The process takes about 10 to 15 minutes to complete. The DNA Test is only required to be administered once*. Once the DNA test samples are obtained and the SkinProfile™ questionnaire is completed, they are placed inside the postage paid envelope and mailed to LAB21 for analysis. It takes approximately 2 weeks for the DNA tests to be analyzed and processed from the time LAB21 receives the completed DNA test samples and SkinProfile™ questionnaire. You will receive a letter from LAB21's Formulation Laboratory informing you of the date when your DNA skincare products will be shipped. All LAB21 products are 100% Custom Formulated. 100% Satisfaction Guaranteed. To place an order, simply call 1-877-695-2221 or click below to order now!
* Please note: The DNA Test is a one time process only. DNA skincare re-orders typically only takes 48 hours to be fulfilled and shipped to the customer.
+++++++++++++++
Worth a browze thru site. Noted comment to scientists in Russia. And they only look at DNA related to the product application.
stakddek
OT: Magical Sky Hook
++++++++++++++++
http://images.google.com/imgres?imgurl=http://www.toysfromtimespast.com/toys/307-2.jpg&imgrefurl...
++++++++++++++++
Sky Hook Price
$3.00 Dimensions
3.5" Long Item #
1307
A Sky Hook is a toy that achieves a balance that looks and feels impossible. It has been known for generations and still today amazes young and old alike. The Sky Hook will balance itself at the end of one's finger under one condition - a leather belt is hung in its groove.
++++++++++++++++++++++++
Stakddek
Miss Scarlet and friends, I'm older than 33 but was there a leap year in there somewhere? Doubt if it makes a difference to the legal beagles, but I sure as heck would want to make sure by multiple written legal opinions that I knew exactly when I had fulflled all my obligations with and re:TBF, and then I'd wait an extra day!
I think that I just may have a vindictive streak, and I would certainly want to make sure that anyone who had messed with me didn't profit from my recovery. I do believe TBF took advantage of Doctor Frudakis, and though it might have seemed like a small risk to the Doctor back when, the economic climate sure slowed things down and made the contract with TBF quite onerous (over-on-us).
Of course implied in this scenario we create for conversation is the implicit hope that DNAP will suddenly be worth a purchase at something over .05 a share to even make it worth TDF exercising it's rights. Oh well it's nice to conjecture a favorable outcome.
I remember when I was a kid, we had a toy, a "sky hook". You could use it to suspend an object (from it) and hang it on a table or door edge and it seemed to defy gravity. Recent weeks have seemed to be the same with DNAP share price. For all the bashing and gnashing of teeth, the share price still seems to hover at that penny mark or very close. The magic is that something is holding the price up, and though many of us are I imagine averaging our investment, I don't believe we are acting alone.
Oh well, musings after midnight are want to suffer in dawns light. I wish you and all our fellow investors well.
Stakddek
Wheel Prices????
++++++++++++++
http://www.tirerack.com/upgrade_garage/WheelSearch.jsp?&autoMake=Hummer&autoModel=H2&aut....
++++++++++++++
2004 Hummer H2 - Wheels 1 through 5 of 8
ASA HM2
20x9.5
$349 22x10
$449
ASA HM3
20x9.5
$349 22x10
$449
EVO Andro 8
17x8.5
$411
EVO Cheyenne 8
20x8.5
$663
EVO Commando
18x8.5
$480 18x9.5
$539 20x8.5
$710
Choose Color---------------YellowBlackPewterRedSage GreenSunset OrangeWhite
Filter by:
Size---------------All17"18"20"22"
Finish---------------AllChrome/Bright
Pricing--------------- Show AllShow Specials
+++++++++++++++++++++++++++
I can't say I follow these wheel prices, and the hummer is using some "big" rims, so without info for comparison, we got apples and oranges, ignoring the asthetic appeal of the wheel trim. (Navy Logo).
Not planning on buying wheels for my ride, and am not even thinking about buying into this stock. I don't want to sound or be like a basher, so I will not be posting here anymore. Just wanted to reply to the post addressed to me. Good Luck to you all, whatever the decisions.
Stakddek
Hi Chris: Hubris. Stakddek EOM
Why Easy, thank you for caring. It just goes to show how concerned you are with our investing. Obviously we are causing you much consternation with our unchartable support for dnap. I realize you areb a technical type guy, and have pronounced on many occassions have foolish our investment and continued support for DNAP is. I hope you will continue informing us of this. Your fervor in this lost cause is good for the soul. Thank you again for all your unselfish efforts. You really are a peachy kean kind of guy to devote so much time and effort here. I'll sleep really good tonight knowing you are hovering about like some guardian angel, making sure that my investment is -- ell just what are you trying to tell me about my investment? And why? If it's a lost cause, I would imagine there is no profit for you. I guess what you call fluff PRs havent created a suitable volume for your investment style. Of course if you're daytrading a hundred thousand,m I guess it's worthwhile, but you seem to be saying it's quite risky? Gosh. You must really be a superswell nice guy superhero type to want to take good care of all us, as you affectionately refer to us, what was it? Dolts? So alltruistic you are. So worthy of Sainthood. Or would you prefer deification?
Stakddek
Chadman & Chucker: I'm not invested here, got my own problem stocks, but I was wondering about wheels for a vehicle I own and was sorta' shocked by the price, and then I was wondering if the wheels they are selling are DOT approved for vehicle use? Wish you luck that this one pulls through. I didn't notice any mention of DOT approval on website, but the cost sort of scared me away.
Stakddek
NYC - ONE CASE?
+++++++++++++++
http://www.nyc.gov/html/doh/html/public/press05/pr016-05.html
+++++++++++++++
Stakddek
<><><><><>
Press Release
New York City Department of Health
and Mental Hygiene
Office of Communications
FOR IMMEDIATE RELEASE
CONTACT: Sandra Mullin/Sid Dinsay
Business Hours (212) 788-5290
After Business Hours (212) 764-7667
Friday, February 11, 2005
NEW YORK CITY RESIDENT DIAGNOSED WITH RARE STRAIN OF MULTI-DRUG RESISTANT HIV THAT RAPIDLY PROGRESSES TO AIDS
Highly Virulent Strain Resistant to Three Types of HIV Drugs Is Rare In Patients Not Previously Treated for HIV; Strain Is Also Associated with Rapid Onset of AIDS
Health Dept. Urges At-Risk Groups To Stop Risky Sexual Behavior; Patients Who Are On Treatment For HIV/AIDS And Are Doing Well Do Not Need Susceptibility Testing Unless Advised By Their Physician
--------------------------------------------------------------------------------
NEW YORK CITY - February 11, 2005 - A highly resistant strain of rapidly progressive human immunodeficiency virus (HIV) has been diagnosed for the first time in a New York City resident who had not previously undergone antiviral drug treatment, according to the Department of Health and Mental Hygiene (DOHMH). The strain of three-class antiretroviral-resistant HIV - or 3-DCR HIV - does not respond to three classes of anti-retroviral medication, and also appears to greatly shorten the interval between HIV infection and the onset of AIDS.
The patient is a male in his mid-40s who reported multiple male sex partners and unprotected anal intercourse, often while using crystal methamphetamine (crystal meth). He was first diagnosed with HIV in December 2004 and appears to have been recently infected. The diagnosis of 3-DCR HIV was made shortly thereafter at the Aaron Diamond AIDS Research Center. Since then, the patient has developed AIDS. DOHMH is counseling and offering HIV testing to those contacts of the patient who have been identified.
While drug resistance is increasingly common among patients who have been treated for HIV, cases of 3-DCR HIV in newly-diagnosed, previously untreated patients are extremely rare, and the combination of this pattern of drug resistance and rapid progression to AIDS may not have been diagnosed previously. Strains of 3-DCR HIV are resistant to three of the four available types of antiviral drugs that are most commonly prescribed: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. This strain also caused a rapid onset of AIDS, which usually occurs more than ten years after initial infection with HIV. In this patient's case, onset of AIDS appears to have occurred within two to three months, and at most 20 months, after HIV infection.
Health Commissioner Thomas R. Frieden, MD, MPH said, "This case is a wake-up call. First, it's a wake up call to men who have sex with men, particularly those who may use crystal methamphetamine. Not only are we seeing syphilis and a rare sexually transmitted disease - lymphogranuloma venereum - among these men, now we've identified this strain of HIV that is difficult or impossible to treat and which appears to progress rapidly to AIDS. This community successfully reduced its risk of HIV in the 1980s, and it must do so again to stop the devastation of HIV/AIDS and the spread of drug-resistant strains. Second, doctors in New York City must increase HIV prevention counseling, increase HIV testing, obtain drug susceptibility testing for patients testing HIV-positive who have not yet been treated, improve adherence to antiretroviral treatment, and improve notification of partners of HIV-infected patients. Third, the public health community has to improve our monitoring of both HIV treatment and of HIV drug resistance, and we have to implement prevention strategies that work."
The Health Department recently issued a Health Alert to physicians, hospitals and other medical providers asking them to test all previously untreated patients newly diagnosed cases for anti-HIV drug susceptibility. The Department is monitoring laboratories for additional cases of 3-DCR HIV in newly diagnosed persons. DOHMH is also working with New York State to establish a long-term system for monitoring drug resistance in HIV-positive patients who have not yet undergone treatment.
Dr. Frieden added, "Patients who are on treatment for HIV/AIDS and are doing well do not need susceptibility testing unless advised to by their physician."
REMARKS BY MEDICAL AND COMMUNITY LEADERS
Dr. David Ho, CEO and Director of the Aaron Diamond AIDS Research Center, said "This patient's infection with an HIV-1 strain that is not amenable to standard antiretroviral therapy, along with his rapid clinical and immunological deterioration, is alarming. While this remains a single case, it is prudent to closely watch for any additional possible cases while continuing to emphasize the importance of reducing HIV risk behavior."
"The rapidly growing crystal meth epidemic in New York city continues to play a significant role in facilitating the transmission of HIV. In light of the emergence of this virulent new strain, health care providers must be especially vigilant in not only recognizing and diagnosing HIV infection, but also in recognizing the signs and symptoms of crystal methamphetamine use in their patients," said Dr. Antonio Urbina, Medical Director of HIV education and training, at St. Vincent's Catholic Medical Center.
"Callen-Lorde is deeply concerned about this newly identified case of multiple drug resistant HIV," said Jay Laudato, Executive Director of the Callen-Lorde Community Health Center. "We urge all persons, both HIV negative and positive, to only engage in safer sex practices in order to prevent new infections or re-infection. For those persons who don't know their status, we urge HIV testing and obtaining the information and support necessary to reduce their risk for HIV infection. We also ask all gay and bisexual men to become knowledgeable about the dangers of crystal methamphetamine and in particular its relationship to sexual risk taking."
Dr. James Braun, President of the Physicians Research Network, said "We believe that the transmission of treatment-resistant HIV was a disaster waiting to happen, particularly in communities where safer sex is not practiced regularly and in light of people using drugs like crystal meth. All primary care providers in acute care settings need to know how to diagnose HIV in its earliest stages and where to refer people so that new infections are properly worked up and treated."
"HIV prevention is an ongoing process," said Ana Oliveira, Executive Director of Gay Men's Health Crisis. We have to double our efforts and resources to maintain treatment and prevention education for people who are infected as well as for those who are not. New Yorkers must be vigilant and know that infection with resistant strains of HIV can be avoided. People living with HIV can live healthy and satisfying lives by protecting themselves and their partners, regardless of HIV status."
Tokes M. Osubu, Executive Director of Gay Men of African Descent, said, "This is the news we have all been fearing. While the recent advances in HIV treatment have led to the improvement of countless lives, we have always known that many people respond poorly to these therapies and for many others, the side effects are devastating. Continued education about staying safe and avoiding HIV remains our most potent weapon."
Dr. Jay Dobkin, Director of the AIDS Program at Columbia University Medical Center, said, "This case is a striking reminder that the risk of getting infected with HIV has not gone away. In fact, risky behavior may be even more dangerous now since there is a chance of infection with a virus we may not be able to treat."
"This case should drive home the point that substance use can lead to unsafe sex, and unsafe sex can lead to infection with a highly drug-resistant strain of HIV that can be extraordinarily difficult to treat and may cause rapid progression to AIDS," said Roy M. Gulick, MD, Associate Professor of Medicine at Weill Cornell Medical College in Manhattan.
Dr. Jack DeHovitz, Professor at SUNY-Downstate Medical Center said, "This finding supports the need for enhanced availability of HIV testing, as well as preventive interventions, which are effective in reducing subsequent HIV transmission."
Know Your HIV Status
There is an epidemic of HIV and AIDS in New York City: more than 88,000 New Yorkers are known to be living with HIV/AIDS, and an estimated 20,000 more are believed to be living with HIV/AIDS and don't know it.
By knowing your HIV status, you can protect yourself, anyone you are having sex with, and, if you are pregnant or planning pregnancy, your baby. Free and fully confidential STD exams and treatment, as well as confidential or anonymous HIV testing, are available at Health Department clinics throughout New York City. Health insurance, proof of citizenship and/or parental consent are not required to receive these services. Please call 311 or visit http://www.nyc.gov/health for a list of clinics and hours of operation.
###
#016
--------------------------------------------------------------------------------
Go to Press Release page // Public Information page // NYC DOHMH Home page // Health Topics // Publications
NYC.gov Home Page // Mayor's Office // City Agencies // Services // News and Features // City Life // Contact Us // Search
Just for conversation:
++++++++++++++++
Home · Submit a Site
SEARCH all magazinesthis magazineArts/Entertain.AutomotiveBusiness/Fin.Comp./Tech.Health/FitnessHome/FamilyNews/SocietyReference/Ed.Sports FOR · Advanced Search · Help
You are Here: Articles > PR Newswire > Jan 26, 2004 > Article
PhenoMed Sdn Bhd Initiating Clinical Trials Program for SARS and Other Infectious Diseases.
PR Newswire, Jan 26, 2004
KUALA LUMPUR, Malaysia, Jan. 26 /PRNewswire/ -- PhenoMed Sdn Bhd, a development-stage disease management and medical-pharmaceutical therapeutic company, announces the initiation of its clinical trials program for infectious diseases.
"PhenoMed is announcing that it will begin collecting information from government agencies, physicians and individual patients interested in participating in the company's clinical trials program. We are working closely with our US partner, GenoMed, Inc., and that company's CEO and Chief Medical Officer, Dr. David Moskowitz, in helping to sign up interested parties," said Ezehan Reza Kamaluddin, PhenoMed's interim Chief Operating Officer. "There is a worldwide need for disease management and targeted pharmaceutical therapeutics directed at infectious disease. Malaysia's disease management needs are ever-present and PhenoMed wants to do all it can to help in meeting the country's healthcare needs. The immediate concerns over avian flu in the region highlights this need."
PhenoMed's US partner, GenoMed, believes it has discovered a way to accomplish the equivalent of vaccination against all viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, an approach already known to be extremely safe from its use, for other purposes, in hundreds of millions of patients since 1978. This patent-pending method is presently under study by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, to test the Company's compounds in tissue culture assays to evaluate potential activity against influenza (the flu) and SARS.
About PhenoMed, Sdn Bhd
PhenoMed is a development-stage disease management and medical- pharmaceutical therapeutic company, with its primary goal being the improvement of patient outcomes through the discovery and application of "genome-aware therapeutics(TM)". PhenoMed is building a network of physician and health services organizations to quickly expand its medical and therapeutic service offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a privately held company located in Kuala Lumpur, Malaysia. For more information about the company, please visit http://www.phenomed.net/.
PhenoMed Contact:
Corporate Headquarters
Ezehan Reza Kamaluddin
Chief Operating Officer (Interim)
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
50480 Kuala Lumpur, Malaysia
ezehan@dnaphenomics.com
http://www.phenomed.net/
About GenoMed, Inc.
GenoMed, Inc. is a next generation disease management company whose mission is the improvement of patient outcomes through the identification of molecular pathways that cause disease. As first reported in a St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html), the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. GenoMed is currently conducting worldwide clinical trials for SARS and influenza A (the flu). In September of 2003, GenoMed obtained an 88% cure rate for this treatment approach against another lethal viral disease, West Nile virus encephalitis. These results will be published soon.
GenoMed Contact:
David W. Moskowitz MD, MA (Oxon.), FACP
314-977-0110
fax: 314-977-0042
dwmoskowitz@genomedics.com
http://www.genomedics.com/
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.
CONTACT: Ezehan Reza Kamaluddin, Chief Operating Officer (Interim), PhenoMed, ezehan@dnaphenomics.com; or David W. Moskowitz MD, MA (Oxon.), FACP, GenoMed, +1-314-977-0110, fax: +1-314-977-0042, dwmoskowitz@genomedics.com
Web site: http://www.genomedics.com/
Web site: http://www.phenomed.net/
COPYRIGHT 2004 PR Newswire Association, Inc.
COPYRIGHT 2004 Gale Group
+++++++++++++++++++++
It is a curious world we live in, and the machinations of the Divine are wont to wreak havoc with the perceptions of man.
Stakddek
Dodge! Slow down! Breathe! Asphixia! Your turning Blue! Don't worry. Be happy. You could be a Desoto!
Stakddek
This is some very dated info on Orphan Drugs. The EU and even our FDA seem to allow a special status and certain allowances for medicines, drugs, tailored for a limited population.
++++++++++++++++++++++
http://www.europarl.eu.int/stoa/publi/167780/default_en.htm
++++++++++++++++++++++
I would presume that many drugs are beneficial for limited populations, but are economically infeasible for "large pharma" to devote in house resources to. Now if there was an outsourcing method, to effectively find the population most likely to benefit economically.... Well better a few bucks coming in than just a write off as a failed avenue.
Stakddek
Few days old, didn't notice it posted anywhere.
++++++++++++++++++++++++++++++
www.sfgate.com Return to regular view
--------------------------------------------------------------------------------
Multiracial patients must 'win the lottery' to find bone marrow matches
- ERIN TEXEIRA, AP National Writer
Monday, January 31, 2005
(01-31) 00:06 PST (AP) --
Luke Do was a lively 18-month-old awaiting the birth of his first sibling when he was diagnosed with a rare form of leukemia.
The hopes of his parents, both doctors in San Jose, Calif., immediately turned to a bone marrow transplant, but they soon learned some distressing news -- Luke's ethnic heritage made him a tough match.
Sarah Gaskins, Luke's mother, has Japanese and European ancestors and his father, Lam Do, is Vietnamese-American. Because bone marrow matches usually are made with a relative or someone with the same racial or ethnic background as the patient, multiracial people rarely have success.
"It's tragic," said Lam Do, who specializes in internal medicine. "Your chance of finding a donor is so low, it's like winning the lottery. And most people are unaware of this."
For years, the medical community has pushed for increased donor registry among racial minorities to improve survival rates for leukemia, lymphoma and other blood diseases. But to the general public, the situation is little known.
Only 2 percent of those who list their ancestry with the National Marrow Donor Program are multiracial, though the NMDP will -- for the first time -- study multiracial patients' medical records this year to better understand what kind of marrow tissue they tend to inherit from their parents. The group also will try to more effectively recruit new potential donors, said Helen Ng, an NMDP spokeswoman.
"Using the patient information we have access to, we're trying to understand a little better the issues they face," said Ng, whose group, with 5.6 million potential donors registered, has the largest such list in the world.
Matt Kelley, president of Mavin Foundation, a Seattle-based advocacy group for multiracial people, says the inattention to the problem reflects society's reluctance to accept today's increasingly complex racial landscape.
"It's a headache," said Kelley, whose group has an ongoing bone marrow program. "The reality is that many organizations are afraid of addressing race period -- they don't feel competent or comfortable -- and when it comes to addressing mixed heritage issues, they don't want to go there, either."
Today, whites in need of a bone marrow transplant have about a 90 percent chance of finding a match, said Dr. Patrick Beatty, an oncologist with the Montana Cancer Specialists in Missoula, Mont., who researches ancestry and bone marrow. For those who aren't white, "your chances of getting a match are pretty remote," he said.
The biological reason has to do with the body's response to infections, Beatty said. Because the world's ancient peoples were exposed to different diseases over millennia, each group developed different tissue antigens, substances that help fight illness.
The descendants of these peoples retain those highly varied tissue antigens, he said, making it tough to match the bone marrow of individuals from different ancestries.
Luke Do's family was elated when, about six months after his diagnosis, they learned a marrow match had been found for the boy with a Japanese-American police officer in Seattle.
Luke struggled for months after the transfusion, nearly dying three times, but hung on in the end. Now the Dos are making plans for him to start kindergarten in the fall -- and to celebrate the third anniversary of his transplant on March 18.
The Rivera family of Los Altos, Calif., is still hoping for a similar happy ending.
Chris Rivera, 24, has fought leukemia with chemotherapy for six years. Chris, who also has Down Syndrome, thrived until last October when he was diagnosed with a more lethal form of the blood cancer. He desperately needs a bone marrow transplant within the next year, according to his mother, Kathy Rivera.
"It's so sad, but he's not a very good candidate for a match and it has nothing to do with the fact that he has Down Syndrome," she said. "It's because my husband is Puerto Rican and I'm of northern European heritage."
Like many others, the family is scouring the community, posting messages on the Internet and praying that a match will be found. They regularly help organize bone marrow registry drives, hoping one will beat the odds and turn up the right tissue.
Much of this activity is taking place in Northern California, home to half of the 10 U.S. cities with the highest percentages of multiracial individuals, according to Census 2000. The cities include Hayward, Stockton and Daly City.
Nationwide, Census data counted about 7 million people of multiracial heritage -- the first time an option was available to check more than one racial category. Mavin organizers estimate that number is closer to 10 million.
Within that group, there are millions of possible ethnic mixes, and therefore millions of potential challenges for someone seeking a bone marrow match. Complicating the situation further, research shows that minorities have greater tissue variation than whites. Africans and their descendants globally have the most variation of any population in the world, "many, many more tissue types than Caucasians," Beatty said, adding that current research is focusing on finding matches with umbilical cord blood and developing matching tissues through engineering.
"Many (multiracial) people have very little contact with entities that recognize them correctly," said Kelley of Mavin, adding that this typically results in hurt feelings and a sense of social isolation. "We don't have that luxury when it comes to people's health."
--------------------------------------------------------------------------------
On the Net:
Mavin Foundation: www.mavinfoundation.org
National Marrow Donor Program: www.marrow.org
URL: http://sfgate.com/cgi-bin/article.cgi?file=/news/archive/2005/01/31/national0306EST0009.DTL
--------------------------------------------------------------------------------
©2005 Associated Press
++++++++++++++++++
Stakddek
Stockboy: They even got our address wrong!
++++++++++++++++++++++++++++++++++++
Senecio News & Publications
President of Senecio Software Inc. to Design and Coordinate DNA Phenomics' Bioinformatics and Web-based Research Initiatives
DNA Phenomics Appoints Dr. Jerry W. Wicks, Chief Technology Officer
KUALA LUMPUR, Malaysia – February 25, 2004 - DNA Phenomics, a biotech company focused on the emerging field of phenomics and the development of genomic-based diagnostic tests and drug discovery, announces that Dr. Jerry W. Wicks will become Chief Technology Officer (CTO), coordinating the company's bioinformatic plan including cluster computing design, data storage, statistical analysis systems, corporate communication technology, data gathering protocols, and software selection.
"Dr. Wicks brings an unusually diverse background and knowledge of statistical packages, hardware systems, software design, and electronic commerce to the CTO position at DNA Phenomics," said Chief Operating Officer, Ezehan Kamaluddin. "As we move into the emerging market of personalized medicine – a market defined by a variety of information and Internet-related technologies – it is essential we have an experienced technologist and scientist like Dr. Wicks to help us achieve our long term objectives. We agreed it was to both our advantages having Dr. Wicks remain President of Senecio Software. This arrangement makes it easier to draw upon that company's development and engineering experience," said Mr. Kamaluddin. "In many ways it is as though DNA Phenomics now has its own software division with all of the talent, resources, and engineering knowledge of that company immediately at hand."
Dr. Shaharuddin Datuk Aziz, DNA Phenomics' Chief Scientific Officer, noted, "Dr. Wicks' decades-long teaching experience at the graduate level in demographic methods, statistical packages, and survey research techniques will be invaluable to us as we implement our clinical genomics protocols, PhenoKit discovery platform, and planned personalized medicine field units. We will draw upon and use all of that experience."
"The opportunities available to DNA Phenomics in the Asia-Pacific region are boundless," said Dr. Wicks. "DNA Phenomics' business plan, world class scientific and management teams, and the growing number of alliances suggest DNA Phenomics could soon achieve a dominant position in the market. Accepting the CTO position was an easy decision for me to make in light of this young company's strengths and its potential for exponential growth."
Dr. Wicks is President and co-founder of Senecio Software Inc., a US-based corporation specializing in the design and production of advanced multi-tier, web-based applications. Dr. Wicks is Professor Emeritus at Bowling Green State University and Adjunct Professor of e-Commerce at the Helsinki School of Economics and Business Administration. For well over two decades, Dr. Wicks conducted research in the areas of population studies, survey research, and software design. As Director of Bowling Green State University's demographic and survey research center, he directed several hundred state, national, and international research projects. His teaching included graduate seminars in applied demography, statistical packages, survey research methods, and computers and society. He teaches the seminar in e-Commerce at the Helsinki School of Economics and Business Administration and regularly serves on scientific review panels at NIH. As co-founder of Senecio Software in 1992, his efforts and those of his colleagues have been directed largely at automating and refining Internet-based, large-scale data collection efforts using an array of web-related software
About DNA Phenomics Sdn Bhd
DNA Phenomics is a development-stage company focused on the emerging field of phenomics and the development of genomic-based diagnostic tests and drug discovery. The company's phenomics discovery platform offers university labs as well as pharmaceutical and life science companies a powerful research tool for uncovering patterns in the genome associated with health factors and drug responses. The company's goal is to become a leader in the discovery, development, and sale of genomic-based diagnostic healthcare products, pharmaceuticals, and biotech research services throughout Asia and the Pacific. Founded in 2003, DNA Phenomics is headquartered in Kuala Lumpur, Malaysia. DNA Phenomics is a privately-held company. Additional information about DNA Phenomics and its genomic-based solutions can be found at www.DNAphenomics.com.
Public Relations Contacts
Corporate Headquarters
Ezehan Reza Kamaluddin
Chief Operating Officer
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
Kuala Lumpur, Malaysia
ezehan@dnaphenomics.com
+++++++++++++++++++++++++++++
I'm bemuddled
Stakddek
Hi all: well I guess we have to thank our lucky stars that some one has charted our future, been able to learn enough about the company to know a fluff PR from a substantitive one, and with all this going on has time to "be on station" to be sure and respond to any DNAP activity with prompt comment. (instantaneous comment I might add.) Thank heaven for all this attention. It reassures me that DNAP is headed in the right direction. Congratulations to us all.
Gee. A very quick and easy way to determine your gene ancestry. Does this have any application to bioinformics?
Gee, chip based. Hmmm. Handheld.
There's something in there isn't there. We musn't forget the big picture when we have the razzle dazzle crew telling us how to think.
Stakddek
Tried a spoonful of sugar, but the medicine just don't go down. Must be that gag reflex again. Never did like sour grapes!
Maybe we all should learn English! Or is that German? Or Chinese? Or Tagalog?
Stakdddek
Over the teeth and through the gums, look out stomach here it comes!
uninebriated. (yet)
I thought the PR was in poor form, but then as I tried to justify it in my mind, I still dislike it.
If we could have said we aided in Carson's recovery, great. But to imply that we are available and if employed by his docs we might have saved him-- well I guess I felt it crossed the line and was a poor subject for a PR, at least the way it was worded.
The only way I could accept that PR coming from GMED and the Doctor, was if it was written in frustration at having tried to help and being told "No, we have it under control.".
Probably not the first time or the last that new treatments that take time to gain acceptance, and this will happen in the medical field everytime something that appears so easy and effective is suggested.
I remember Carson from his "Who do you Trust" days. He kept the nighttime entertainment shows alive. He built on the TV style of the original "Tonite Show" that Jack Parr and Steve Allen and Ernie Kovacs had pioneered, perfected it and made it his own. I will miss him and look forward to catching the retrospectives about his career that will follow.
Stakddek
Call me cynical but, given that LJC has to sell, (to avoid excess of 5% ownership) and the next months LJC purchase is predicated on the average of so many days closing prices, well the big dip today sure looks suspicious to me.
Of course there have to be buyers and sellers, but it looks like someone is timing things for advantage. Oh well. Hope some of you long termers had a chance or get a chance to average down, (like I did) and let's hope that good news is forthcoming from DNAP.
Stakddek
A fuzzy photo? Maybe a sculpture?
++++++++++++++
http://www.3dsystems.com/products/multijet/index.asp
++++++++++++++
We've all seen the foreensic recreation of the mummy faces, the art used to create a "bust" of long long removed ancestors. Much skill and yes artistry goes into these facial reconstructions. I wonder if a little cross polinnation might be in order with DNAP? Perhaps certain gross features presentable in 3d are not as "vibrant" in a two dimensional photo. If the biometric info is quantifiable and can be "translated", it might be possible to "reconstruct" a face when the only clue is a single tooth with viable DNA. A DNA modeled sculpture might be useful as a source of biometric information simply using the common biometric qualified scanners for input. That image would then be used for comparison against the millions of images gathered each day. Perhaps there is no need for this model as possibly they can just work with the numbers to do this now. But then, when you present to the jury in a case, intangible mumbers against a solid object, most people are more comfortable relying on something they can touch and feel.
Might give Zach Gaskin another angle for his demos.
Stakddek
++++++++++++++++++++++++++++++++++++
InVision 3-D printer
InVision HR 3-D printer
InVision Finisher
Thermojet Printer
Multi-Jet Modeling (MJM) Products
--------------------------------------------------------------------------------
There are virtually no limits to the benefits our customers, and ultimately consumers, realize when 3D Systems solid imaging solutions are employed to accelerate design and development projects.
With 3D Systems' multi-jet modeling products, you'll iterate designs more quickly, and move to more mature designs in less time and at lower cost than ever before. More mature designs translate to improved product quality, where decisions are made based on feedback from more people involved in the design project — management, co-workers, suppliers and vendors, your toolmaker, customers and clients, and even prospects.
Ensure that your designs are manufacturable. Present your designs in their best light, in the most intuitive way possible - as a physical 3-dimensional model. You'll get unsurpassed responsiveness, improved feedback, and better decision making - to ensure that your design is all that it can be.
Your organization will appreciate the results - better designs, fewer engineering change orders, fewer product defects, less tooling rework, and improved product success.
The InVision™ 3-D printer and ThermoJet® solid object printer offer two exciting options to gain these improvements within your organization.
The InVision 3-D printer automatically produces robust, superior quality and affordable models for design communication, "form" communication and preliminary assembly analysis applications."
The ThermoJet solid object printer is your best choice if you desire wax-based models and patterns for investment casting, or other molding or casting applications. In addition, the ThermoJet printer produces highly detailed wax models for design communication, where wax is the desired material or where upfacing surface details are critical features you wish to communicate.
Both of these tools have now become the most efficient manner in which a designer can go from creation to reality. As designers around the world are learning, 3D Systems' products allow them to communicate the way they design — in 3-D.
++++++++++++++++++++++
Hey Arch, I hear they're gonna' change the Social Security system. Maybe we can buy conterfeit shares from DTC? On the other hand the Mayan calendar ends in I believe December 2012 and the bible codes predict an earth destroying collission about the same time. I guess all these guys are stalling until then.
My expectation is that all the unfulfilled transactions will trace back to an overseas broker that is run by three or four people who have been dead for 20 years. Sort of wipe the slate clean, no assets to divide, no lawyers to pay, and no one goes to jail. Problem solved.
Of course I'm being to hard on our legislators and those nice folk at the SEC. I mean after all, if anybody had brought this to thier attention, they would have taken care of it right away.
The reg SHO is nice, but how does it apply to say, the Berlin Stock Exchangeand other foriegn brokers? Can't they just keep "bouncing" the make believe shares amongst themselves? Sorry I just ask the dumb questions, and hope someone has a good answer to satisfy my incredulity!
I'm sorta' like that guy who ran that big company, you know the one that cooked the books and had 15 billion in debt? His defense is "I'm not a trained CEO so I didn't know all that fraud was going on." "I thought everything was peachy." I guess that when you're living that high on the hog, it's rough to see exactly what those so distasnt evil underlings are doing eith your company!
Granted these people may all get the eternal reward they deserve in proportion to the harm they caused to so many people, but I sure would like to have my Kharma adjusted by seeing the comeuppance start real soon! Not that I should be vindictive and wish draconian punishments on them, but sometimes you have to have a few good examples to assure others of an equal or lesser character that crime doesn't pay. I sort of figured that after all thier assets are seized they should be given the opportunity to work off the remainder at minimum wage.
Paraphrasing a recent letter I saw about how to tell if you live in California:
" If you drive illegally here they take away your license. If you're here illegally, they give you a license!"
Stakddek
On the Ceramic Front: BIPH News Release. My Further comments at conclusion of cut and paste.
++++++++++++++++++++++
Press Release Source: Biophan Technologies, Inc.
Biophan to Demonstrate New Ceramic Motors for Medical Device Applications at Major Industry Conference
Tuesday January 11, 1:34 pm ET
Advanced Technology Enables High-Precision Implantable Drug Delivery Systems and Other Uses
ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 11, 2005-- Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, will demonstrate its proprietary ceramic motors for use in a wide range of medical and life science devices at the Medical Design and Manufacturing West (MD&M West) conference, January 10-12, at the Anaheim Convention Center in Anaheim, California. The announcement was made by Michael Weiner, CEO of Biophan. Biophan is the exclusive worldwide distributor for medical applications of the SQUIGGLE(TM) ceramic motor, produced by New Scale Technologies.
ADVERTISEMENT
The MD&M West conference, organized by Canon Communications, LLC, is one of the world's largest meetings for medical device designers and manufacturers. It is being attended by thousands of key designers, decision-makers, and medical device industry executives from the United States, Europe, and Asia.
Biophan is showcasing innovative solutions based on its patent-pending direct linear drive motor constructed of advanced ceramic materials. The motor's unique, high-precision design involves only four parts--compared with hundreds for previously available products--that affords exceptionally high levels of dependability and performance. The SQUIGGLE motor offers a new positioning solution and can be easily scaled to fit a variety of sizes and advanced biomedical devices, including implantable drug delivery devices such as insulin pumps and implantable drug pumps, as well as precision dosage metering and microfluidic devices.
"The piezoelectric ceramic technology we have perfected allows the SQUIGGLE motor to be manufactured in a wide range of sizes and configurations, especially at very small sizes and low power," explained David Henderson, President of New Scale Technologies and inventor of this motor. "Our technology provides substantial advantages over other available biomedical motors. These advantages, such as safety and compatibility with Magnetic Resonance Imaging (MRI), have the potential to significantly improve the options available to the health care and bioscience industries."
Additional technical features of the SQUIGGLE ultrasonic motor includes nanometer precision, zero magnetic fields, no ferromagnetic materials, ultra-low outgassing, negligible heating, quiet movement, and consistent operation over a wide temperature range. The SQUIGGLE motors have been demonstrated from room temperature to 100 degrees Kelvin--or some 173 degrees below the freezing point of water. NASA's Goddard Space Flight Center is evaluating the ceramic motor technology for use at 4 degrees Kelvin--nearly absolute zero--for space applications.
Biophan will also highlight other advanced technologies at the MD&M West conference, including technologies for enabling interventional surgical devices or implants to be made MRI-safe and compatible. These technologies are being developed to enable a new generation of MRI-guided surgical procedures. The Company will also feature its recently announced patented anti-antenna technology for improving the safety of medical implants under MRI.
"We're very excited about highlighting our ceramic motor designs as well as our other recent achievements in development of medical device solutions," said Mr. Weiner. "Biophan is at the forefront of research and development of the next generation of biomedical devices, and our proprietary technologies advance the capabilities of devices across a wide spectrum of diagnostic and therapeutic procedures."
Biophan will be working with the medical device engineering community to use the Company's innovative ceramic motor and its MRI safety and imageability technologies to enable a range of new health-care and life-enhancing products.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 25 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
--------------------------------------------------------------------------------
Contact:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
(Press Interviews)
Jennifer Gould, 212-843-8037
--------------------------------------------------------------------------------
Source: Biophan Technologies, Inc.
++++++++++++++++++++
Real conjecture:
Ceramics in space. Well, we all remember shuttle heat tiles, but what of the newest NASA and Defense Dept."black" applications????
Ramjets with varying thrust chamber shapes, hydrogen fuel burning? Ceramics at near absolute 0Kelvin. From Micro to Macro ceramics needed. Heck, one of the chefs on a TV show was using a ceramic looking blade the other night. How 'bout a ceramic razor blade assy for a triple or quadra track???
Chuckman: If you put Velcro on a belly band you can lock the laptop in place and it won't slip when you type! Great to hear you're recovering. Get up and around soon.
Stakddek
Update at bottom to old news. Statins going over the counter. --Well the patent ran out, and they milked us.... well anyway read the story. There is a genetics angle re; high cholesterol individuals and a search for them.
++++++++++++++++++++++++++++
http://www.ich.ucl.ac.uk/pressoffice/pressrelease_00213
+++++++++++++++++++++++++++++
--------------------------------------------------------------------------------
Date: 12 May 2004
Should cholesterol-lowering drugs be sold over the counter?
Experts in treating patients with inherited high cholesterol have criticised plans to sell cholesterol lowering statin drugs over the counter. They point out that the over the counter drugs will be sold in too low a dose for these serious cases; that it could inhibit hunting down 100,000 patients who have inherited high cholesterol and who do not know it; and that a package of statins, and health advice on diet exercise and smoking tailored to individual needs, is more likely to save lives.
Background
It has recently been announced that a brand of statins, cholesterol lowering drugs, is to be sold over the counter. This statin, and some of the other older statins, has been taken by some patients for 10 years or more with very good effect on lowering cholesterol and reducing heart attacks. Some people do develop side effects, but this is rare and in general these drugs are seen as safe and very useful, although other more powerful types of statins have been introduced recently.
When a doctor prescribes a statin the patient is always monitored afterwards to make sure the drug is being effective in lowering cholesterol, and that there is no evidence of any damage to the liver. Patients being treated in this way are also given information about healthy eating, life style advice such as increasing exercise to help weight loss and also offered help to stop smoking. Since heart disease is not simply caused by one factor, this “whole-patient” approach is widely recognised as being the best way of reducing risk. This is endorsed by guidelines recently brought out by an umbrella group of European doctors including experts in managing cholesterol in the blood, high blood pressure, nutrition, and cardiology. Similar approaches are recommended by doctors in the USA.
So what do leading experts say about the idea of selling statins over the counter?
Professor Steve Humphries from London IDEAS Genetics Knowledge Park is a leading expert in the genetics of cardiovascular disease. One of his major projects is to track down 100,000 Britons who have undetected familial hypercholesterolaemia (FH) – inherited high cholesterol. – which puts them, and roughly half or their relatives, at dramatically raised risk of heart attack. He is helping to organise a project, funded under the Government White Paper on Genetics released in June last year, to track down the relatives of people with FH who often don’t know they are at risk.
Professor Humphries says “The idea of selling statins over the counter raises a number of issues. People with FH will need a lot more than the low dose of statin that is being made available over the counter. Taking this pill, instead of being seen by an expert doctor, will leave them at high risk. Worse than that, the family may not come to the attention of the teams tracing the relatives and they will not be offered the tests to find those who need effective statin treatment.
Dr Ian Hopkinson, a GP based in London added “Statins, together with a healthy diet, regular exercise, not smoking, and blood pressure monitoring, are one part of an approach to reduce the risks of heart disease. The overall approach to reducing the risks of heart disease is likely to be most effective in general practice. Blood cholesterol and blood pressure monitoring are an opportunity for the GP to obtain a detailed family history of heart disease, allowing the detection of other family members who may be at increased risk of developing heart disease.
Professor Humphries is available for interview.
Contact information:
London IDEAS Press Office
020 7829 8671
Notes to editors:
The statin concerned has come off patent, and therefore is being developed as an over the counter drug. What's New
04 January 2005
Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH
Tel: +44 (0)20 7405 9200, Fax: +44 (0)20 7829 8643
and The Institute of Child Health, 30 Guilford Street, London WCIN 1EH
Tel: +44 (0)20 7242 9789, Fax: +44 (0)20 7831 0488
Contact us
++++++++++++++++++++
Stakddek
Thank you for your Con opinion Money4nothin
Hi folks. I find myself failing to remember that this dilution is not like the other pennies I've seen. They have "printed" shares to fatten the prefferred few. DNAP is "printing" shares (taking a little from each of us) to accomplish a major purchase and expansion. We will eventually be co-owners, possibly majority owners of Biofrontera. We will have an in with the Euro market and some sophisticated people who are doing research that complements the DNAP genomic work. They even have product approaching approval and launch! The two companies have been working on the same problems from two different directions. In order to "buy" these benefits, we have to put a little piece of "our" DNAP on the market. It all breaks down to "Do you believe?". I believe, but I've been burned so many times I get a little antsy when I'm not in control. People who know how to do this kind of deal like Gabriel and Tombourini are my delegates, and I sure wish they would, or could, tell me more. It would reassure me. But I can accept that this is big business and if know then everyone would know and that might not be a good thing to have everyone know. Could blow the deal.
So I'll just have to pace the floor like an expectant father, not knowing when the baby is due, but I have faith that the medical staff is the best at what they do. I'm reassured by that, but boy am I one tied up in knots Nervous Nelly! From the tone of this board, I'm not alone in wanting to pass out the cigars, but I'll have to just hope the fingernails last!
Stakddek
Thanks Infida: I guess I'll let my wife stick to doing all the bargain hunting! I always overpay.
Stakddek
Team, that's a loan of 250K US dollar ++ if I calculate it right from todays rate. Much appears to depend on Biofrontera IPO and it's timing. Seems more a good faith gesture than anything else. DNAP get's bucks and interest back, or stock. Noted the loan and arrangement are specified to be adjudicated in Germany if any legal questions arrise. Guess we are all going to need to learn German to keep up with all that's happening.
Auf weidersehen,
Stakddek
3 filings today.
++++++++
DNAPRINT GENOMICS INC 10QSB/A 1/3/2005 6/30/2004 People
DNAPRINT GENOMICS INC 10KSB/A 1/3/2005 12/31/2003 People
DNAPRINT GENOMICS INC S-2/A 1/3/2005 People
+++++++
http://yahoo.brand.edgar-online.com/default.aspx?cik=1127354
+++++++++
Stakddek
OT: Chuckermanfla: Ain't technology wonderful! We would have had to leave you for the wolves in the old days! Godspeed on your recovery. Maybe soccer may be out of the question but I'll try a game of shuffleboard with you anyday. Get better soon and be back here posting.
PS: Who builds those big ovens for Cetek? Probably that company that sold those ovens to England. Ohh? Nevermind!
Stakddek
PS: Apologies to Gilda Radnor.
Easyman: My comment was for the situation created by the manipulators who caused the fall of this stock from it's intitial levels. There were those who traded and bashed to dump and then others who traded and pumped to dump. any of the rest of us who have kept the faith with DNAP, (many longer than I) were burned by this manipulative activity. I can't say that DNAP suferred shorting because I don't know. I did see the continued bashing and pumping that occurred on these message boards.
My regret is the manipulation cost all the shareholders in the company, and seemingly, those that had the most faith in the company and didn't trade the stock for all the time they held it have been hurt the worst by the manipulation. Say you had never bought any DNAP, and turned on your computer Monday and decided to take a chance on a penny stock. How much would it cost you to by your ticket to the moon? I have averaged down, but my average is still above the current share price. I'm sure others are in the same boat. We have faith in the company and management, but feel the day to day manipulation of the stock has hurt the long term holders the worst. Maybe I'm just not a smart trader and am alone in this. I'm not able to swing enough dollars in stock to play the game and so I suffer. I see thrash companies bouncing from pennies to dollars and DNAP just languishes or decreases in pps.
I am bitter about the situation and regret that some folks who bought early and held every share have been burned by manipulation that goes beyond market forces. The initial and the continued faith expressed by the long term shareholders is going to be rewarded, but the shares tricked out of the hands of other investors, and the money they lost will go to the manipulators who have paid so much attention to this stock. I am not bitter about DNAP. I am bitter about all the manipulators who probably have and will be rewarded for what they have done. Those who have held the longest and the bravest will be rewarded as well. But no where near what they deserve for that continued faith they have placed in DNAP.
DNAP must do what it has to to stay viable. DNAP has to garner funds for the new purchase and efforts worldwide. The manipulation that has created a skewed picture of the company, it's management, and it's prospects has cost us all and will continue to cost us in the months ahead. Bashers have created an environment friendly to them and harmful to long term investors. Bashers can't be punished and long term holders can't be rewarded at the levels they deserve. That's just the way it is and I express regret for a system that allows such inequity. It almost seems like the greatest monetary reward goes to the least concerned with what the rest of us invested for.
We saw promise of a "new medicine" that would help all mankind. We saw promise of new investigatory techniques that would aid law enforcement in the search for truth. We saw pots of gold for all of us at the end of the rainbow, and we didn't have to invest in some new way to kill or rob people. A lot of idealist populate the DNAP boards, and we hold the dream very dear. We have stayed the course for many years because we see the dream of Doctor Frudakis coming to fruition. But we all know and realize that our early involvement, our continued support has cost us all for keeping that faith. I'm not beyond feeling good about my investment in DNAP. I see bright promise and a pot at the end of the rainbow. I just wish so many people who only used the promise of DNAP as an opportunity to profit hadn't trampled the rest of us on the way to the reward we deserve. I regret they will get no comeuppance, and I especially regret that those who held firm to the dream, no the promise of DNAP, have lost a portion of a just reward to the doomsayers who have continually tried to destroy all our dreams.
Stakddek
A Healthy, Happy, Prosperous NEW YEAR to all! We can disagree about DNAP and have different market strategies, but HAPPY NEW YEAR anyway.
To all the stalwarts who have expended so much effort to make this more than an investment, I thank you for all the time and effort you have expended. I fully expect a climb out of this trading level and I think we will all see a prosperous DNAP NEW YEAR. I regret that the faithful who have held those early shares are not able to be rewarded for that perserverance they have shown. I can't begin to thank you all, but to say HAPPY NEW YEAR.
Stakddek
NYTimes Story -predictor????
++++++++++++++++++++
December 17, 2004
Study Suggests Way to Predict Whom Antidepressants Help
By BENEDICT CAREY
cientists studying depression reported yesterday that they had found evidence that a common genetic variation affecting how people manage stress predicts how much benefit they get from taking antidepressants.
Psychiatrists have long known that about half the people found to be suffering from depression also show signs of elevated anxiety. Researchers have tried to explain the correlation, as well as why the same drugs can relieve both conditions.
In the new study, published in the journal Molecular Psychiatry, doctors from Harvard and the University of California, Los Angeles, treated with drugs a group of 54 Mexican-Americans in Los Angeles who were both depressed and highly anxious. (Limiting the study to one demographic group was a control tool.) They found that 60 percent of the group had a common genetic variant that helps govern the body's response to stress.
The researchers found that after being treated with antidepressants, patients with the genetic variation were far less anxious and depressed than when they began the study, said the lead author, Dr. Julio Licinio of the Neuropsychiatric Institute of the University of California.
But anxious, depressed patients who did not have the variation got much less relief from the drugs, Dr. Licinio said, adding, "This is the first time we've linked response to antidepressants to a stress-related genetic variation."
++++++++++++++
From little acorns...
Stakddek
Sony to discontinue plasma // go with LCD.
++++++++++++++++++++++++
Sony to exit plasma TV business, shift focus to LCD models: report
27 minutes ago
TOKYO (AFP) - Sony Corp (NYSE:SNE - news) (news - web sites). plans to withdraw from the plasma television business as early as the first half of 2005, a news report said.
+++++++++++++
+++++++++++++
The consumer electronics giant instead will devote its flat-panel TV operations to LCD (liquid crystal display) versions, the Nihon Keizai Shimbun said without citing sources.
By consolidating its business resources and concentrating its investments in LCD TVs, Sony is aiming to enhance its price competitiveness in the global market and recover its profitability, the newspaper said.
As part of its plan to withdraw from plasma TVs, Sony will phase out manufacturing of these units at production sites in the Japanese city of Ichinomiya, Spain's Barcelona, China's Wuxi and the US city of Pittsburgh, the Nihon Keizai said.
The company is considering a plan to stop selling these sets as early as the first half of next year but will continue to provide aftersales services to customers who purchased them, it said.
The production lines at the four sites are expected to begin producing LCD TVs and rear-projection models in place of plasma sets, the newspaper said.
Sony is the world's biggest TV manufacturer, taking up roughly a 10-percent share of the global market, the Nihon Keizai said.
Its decision to withdraw from plasma models could have an impact on other domestic and overseas TV makers, it added.
Sony officials could not be reached for immediate comment.
+++++++++++++++++
Stakddek
Matt agree with Chris. Better to license the tech and let the free market pay for the use without giving anyone party the whole cow. Continued revenue from multiple sources. Continued input from multiple users to R&D about improvements or problems, that will make the product stronger and more valuable. Got to make it a "standard procedure" for investigative screening. Granted down the list after CODIS search turns up no hits, but given investigative costs, it's very economical. We shouldn't kill the goose but keep harvesting the eggs!
An opinion based on my total lack of knowledge of any internal information and what the needs of DNAP are!
Stakddek
Orch CEO leaving? DNAP expanding into more avenues than the current management can handle comfortably? Well I don't know. Seems more probable than soap opera plots though.
Dang kids watch to much TV. Parents should have better control. Kids should be doing homework instead of posting on bulletin boards.
Stakddek
OT: Jackson DNA -- Random test to make sure Jacksomn tested in prior samples is still or was real Jackson. Sadaam had how many doubles? Of course none of them could moonwalk!
Stakddek
Govt grants or funding???
Somewhere in the back of my mind is the little voice saying that when you take money from Uncle Sam, he wants to be a silent partner and have a big say in the direction of the research, and if the grant leads to a lucrative commercial operation, he'd like a little bit of that too, in addittion to the taxes.
Now I see no harm in a goverment GRANT with no strings attached, but I sure would rather hold my head high and be beholding to no one except my shareholders when my research/product/ became a commercial success.
I would be very against becoming involved with a grant from any source that gives the granting organization an interest or control of any product or process developed for commercial application from that grant.
On the other hand, I have no qualms about paying the taxes on the profits, and I would not be against DNAP providing a few grants of it's own some day in the near future.
The Buffulo DNA chase seems to involve DNAP, as inferred from the classifications of ancestry we've seen published. Perhaps we are about to see a few news stories about the little company in Florida, "THAT AS AN OFFSHOOT TO IT'S DRUG ----" developed the forsenic tool that has been instrumental in two major cases since coming into the investigative toolkit less than two years ago. I do hope that whoever is at this moment writing the PR that will be released after the Buffalo Police have announced a solid capture, will play up the angle of DNAP's medical applications. Wouldn't hurt to let the public know that this pony has many more than one trick!
I would fully expect additional news coverage after a Buffalo capture, and this time, with two "big time" apprehensions aided by DNAP, DNAP is the story. Let's let the reporters play up on how that DNA-wittness is an adjunct to the medical applications, drug efficacy and testing individuals to find out beforehand, what can work best for that individual.
<><><><><> (goes off on a rant!) <><><><><><>
Tie that into the current fear of the FDA approved suicide pills that big pharma foists on us for profit, while overcharging us claiming R&D is expensive. Unfortunately, I guess these pharmas consider thier legal defense fund part of the R&D budget. I wonder how the budget is in a big pharma, what with all those treats for the doctors to get them to prescribe "x" instead of "Y". Considering they all compete to raise physician awareness, wouldn't it be nice if they'sd just say, "x" isn't as effective as "y", and we're withdrawing it and going back to the lab to make a better product? No friends, I'm afraid I've yet to see a report where that happens. Perhaps one of you with your extensive research in this field have heard of some "our product has been superceded by a better product by a competitor and we are going to cease production of "x" until we can make it better or provide a new improved than "y"." Or have we all just seen more marketing? Why are drug companies advertising on TV, with adds that are aimed at promoting a product THAT IS A PRESCRIPTION ? Why is there little print on the screen warning of adverse side effects? I'd prefer my doctor knew all this. I don't need to be enticed. I trust my physician to prescribe what's going to work for me, and not for the benefit of marketers and bean counters at "X" company.
We all know DNAP is fighting an uphill battle against an entrenched foe. That foe is numerous and well funded. The battle is ongoing, and I don't even know for sure when it started. Perhaps when DNAP first started, pharma noted and kept a weather eye. The battle is joined now, and pharma has been slapped hard by a scientist at the FDA. People are concerned and aware of track record pharma has created for pricing schemes and marketing tactics that bear a greater resemblance to a "pirates code" than the Hypocratic oath. Throw in an FDA that is more interested in approving the big boys products, (that's where the money is for those post-government service jobs), and you have a scandal about to really explode. I hope DNAP is prepared to at least publicize the promise of it's research so that the public can mull over the concept of tailoring the drugs you are prescribed by "who you are" and not by who profits!
Stakddek
Gunnabeone: Please remember that you are addressing an entity with an honorific. -- By the way if that old automatic is starting to slip, we have a trannyshop near me run by a DR. Nick.
I note of recent origin the plethora of important sounding names. You know like couldn't mini-drive be used as a handle ? What about M2-Little-Pop?
I think the cloak of respectability donned in the non-de-plumes may just harbor the Emperors New Clothes, and we will all be less than impressed when full disclosure occurs.
By the same standard, if asked to comment on Doctor Cal I would be forced to admit that what he has said in the posts I've seen strikes close to what I perceive. But then I've grown much more cynical over the years. Then somehow he walks the walk and talks the talk. Even then I am still uneasy with any new names I run across. Takes a while to know the players by thier actions and not by thier "character on a BB".
My gut tells me that we don't have as long to wait as some think. My head tells me the road ahead may be the roughest part. Now all we really need is Michael Chreigton and Tom Clancy to start posting here!
Lets hope your "oneday" is really soon!
Best Wishes,
Stakddek
ABC NIGHTLINE- 11:30PM EDT FDA WHISTLEBLOWER-- EOM
Chucker: For your perusal!
+++++++++++++++++++++++++++++
'Beer' Investment Plan
I thought I'd pass along this financial advice I received recently (via email of course):
If you had purchased $1000.00 of Nortel stock one year ago, it would now be worth $49.00.
With Enron, you would have $16.50 left of the original $1,000.00.
With WorldCom, you would have less than $5.00 left.
But, if you had purchased $1,000.00 worth of Beer one year ago, drank all the beer, then turned in the cans for the aluminum recycling price, you would have $214.00.
Based on the above, current investment advice is to drink heavily and recycle.
It's called the 401-Keg Plan.
+++++++++++++++++++++
The data is a little off, but darn, I'm thinkin' about giving the plan a try! Maybe instead of buying more stock I'll buy that grand of beer, and then when I wake up I'll check my account! If things are still bad, I can still buy another $214.00 worth of beer, and try again! Sort of averaging down I guess.
Depending on your personal market outlook, it might be worth considering quantity over quality, or perhaps a mixed portfolio of domestic and off shore. Could we start a sudsfund?
Best of luck with all your investments.
Stakddek
OT: Matt thank you for the comment letter to us on the ignore function. I found that if I membermark someone, and then ignore them, I get to see the number of postings they make, without ever seeing any of the posts! This for some reason is particularly satisfying to me, and I derived some amusement from the knowledge that I had been spared some 40 plus messages, a long blast indeed, and I didn't even note any interplay by other posters to the entity I ignored!
Thank you for the heads up on the ignore. As with many things in life, the lack of exercise (of the ignore function)can lead to our forgetting how to do things for ourselves.
Stakddek